ITP
MDGL icon

Iron Triangle Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Iron Triangle Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-58,378
Closed -$26.8M – 37
2025
Q3 		$26.8M Buy
+58,378
New +$21.8M 3.81% 13

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Iron Triangle Partners's MDGL Position: Q4 2025 in Review

Iron Triangle Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 58,378 shares — an estimated $26.8M sold.

Iron Triangle Partners first reported a position in MDGL in Q3 2025 and held it in 1 quarter. The position peaked at $26.8M in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Iron Triangle Partners reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Iron Triangle Partners sold 58,378 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $26.8M.
  • Iron Triangle Partners first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Iron Triangle Partners's Madrigal Pharmaceuticals position peaked at $26.8M in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Iron Triangle Partners's 13F filing for Q4 2025, filed 17 Feb 2026.